/Company Directory

/

Asset Brief

SNT-5505 (amsulostat)

SNT·Syntara·Low-risk myelodysplastic syndromes (MDS) — a bone marrow disorder causing low blood cell production, often requiring regular red blood cell transfusions·Phase 2·[ TODO: fill in ]

Plain-language Brief

The trial in plain terms

The disease: Myelodysplastic syndromes (MDS) are a group of blood cancers in which the bone marrow does not produce enough healthy blood cells. Low-risk MDS refers to patients classified at the lower end of standard prognostic scoring systems, where the immediate risk of the disease progressing to acute leukaemia is relatively low but quality of life is significantly affected by anaemia and dependence on red blood cell transfusions. Many patients with low-risk MDS require ongoing transfusions because their bone marrow fails to produce sufficient red blood cells. Reducing or eliminating this transfusion dependence is a key goal of treatment in this setting.
What the asset is trying to do: SNT-5505 (amsulostat) is a small molecule drug being studied in combination with ASTX727, an oral hypomethylating agent (a drug that can reactivate silenced genes in cancer cells) that combines decitabine and cedazuridine. The specific molecular target of SNT-5505 is not disclosed in the available data. The MESSAGE study evaluates whether the combination of SNT-5505 and ASTX727 can reduce transfusion burden in low-risk MDS patients.
What the trial is measuring, and why it matters: The MESSAGE study is measuring the effect of SNT-5505 combined with ASTX727 on transfusion burden in low-risk MDS patients. Transfusion independence (the ability to go without red blood cell transfusions for a sustained period) and transfusion burden reduction are clinically meaningful endpoints in this setting because frequent transfusions carry risks including iron overload and reduced quality of life.
Efficacy benchmarks in this setting: In low-risk MDS, luspatercept (an erythroid maturation agent) demonstrated a transfusion independence rate of 38.2% in the MEDALIST trial versus 13.6% for placebo among transfusion-dependent patients with ring sideroblasts (per Fenaux et al, New England Journal of Medicine 2020). Luspatercept achieved a transfusion independence rate of 58.5% versus 31.2% for placebo in the broader lower-risk MDS population in the COMMANDS trial (per Garcia-Manero et al, Lancet 2023). ASTX727 (oral decitabine/cedazuridine) has been studied separately in MDS, with haematological improvement rates reported in its own clinical programme (per Garcia-Manero et al, Journal of Clinical Oncology 2021). Any early-stage figures from the MESSAGE study are not statistically comparable to these results given differences in study design, patient populations, and trial maturity.

Trial Design

Design summary

Phase: Phase 2
Design type: [ TODO: fill in ] (MESSAGE study — combination of SNT-5505 and ASTX727 in low-risk MDS; further design details not available in provided data)
Primary endpoint: [ TODO: fill in ]
Key secondary endpoints: [ TODO: fill in ]
Enrolment target: [ TODO: fill in ]
Current enrolment status: [ TODO: fill in ]
Sites: [ TODO: fill in ]
Expected readout window: Interim data expected in the second half of 2026 (per Syntara company notes); full primary completion date is [ TODO: fill in ]

Asset Track Record

Did SNT deliver against its own guidance?

Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.

5 July 2026data readoutEncouraging SNT-4728 Phase 2 iRBD resultshit · positivesrc ASX ↗
30 June 2026regulatory decisionEMA Orphan Drug Designation decision (MF)overdue
30 June 2026regulatory decisionFDA feedback on myelofibrosis development planoverdueASX ↗
30 June 2026data readoutPhase 2 MF combo (ruxolitinib) efficacy data readoutoverdueASX ↗
10 June 2026financingResults of Share Purchase Planhitsrc ASX ↗
14 May 2026financingUpdate - Proposed issue of securities - SNThitsrc ASX ↗
13 May 2026financingShare Purchase Plan Offer Booklethitsrc ASX ↗
28 Apr 2026regulatory decisionAmsulostat (SNT-5505) FDA — Positive FDA feedback for Amsulostat P2b trialhit · positivesrc ASX ↗

Class Catalyst Calendar

What's landed, what's next for SNT-5505 (amsulostat) and peers

SNT-5505 (amsulostat)'s own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for SNT-5505 (amsulostat). Showing past 6 months and next 12 months · 8 later hidden.

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

Trial design comparison

How SNT-5505 (amsulostat) reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
SNT-5505 (amsulostat)	Syntara	Small Molecule Other	Phase 2[ TODO: fill in ]	[ TODO: fill in ] (MESSAGE study — combination of SNT-5505 and ASTX727 in low-risk MDS; further design details not available in provided data)	[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	0
A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

Mechanism trade-offs· 2 classes comparedexpand ›

Mechanism	Speed to patient	Manufacturing	Best approved result	Durability	Moat
Fc Fusion ProteinFc-fusion trap	Off-the-shelf	Biologic	Eylea / Vabysmo class	Dosing-interval driven	High (incumbents)
Antisense oligonucleotideASO	Off-the-shelf	Synthetic	Approved (SMA/DMD)	Chronic dosing	Moderate

Curated Commentary

Third-party coverage(none curated yet)

expand ›

External analyst notes, journalism, and industry commentary cited with attribution.

No third-party coverage curated for SNT-5505 (amsulostat) yet. Broker coverage of Syntara is thin; named analyst notes will appear here as they become available. For now, see the company's ASX announcements and the linked sponsor / class sources elsewhere on this page.

Asset Track Record

Did SNT deliver against its own guidance?

Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.

5 July 2026data readoutEncouraging SNT-4728 Phase 2 iRBD resultshit · positivesrc ASX ↗
30 June 2026regulatory decisionEMA Orphan Drug Designation decision (MF)overdue
30 June 2026regulatory decisionFDA feedback on myelofibrosis development planoverdueASX ↗
30 June 2026data readoutPhase 2 MF combo (ruxolitinib) efficacy data readoutoverdueASX ↗
10 June 2026financingResults of Share Purchase Planhitsrc ASX ↗
14 May 2026financingUpdate - Proposed issue of securities - SNThitsrc ASX ↗
13 May 2026financingShare Purchase Plan Offer Booklethitsrc ASX ↗
28 Apr 2026regulatory decisionAmsulostat (SNT-5505) FDA — Positive FDA feedback for Amsulostat P2b trialhit · positivesrc ASX ↗

Class Catalyst Calendar

What's landed, what's next for SNT-5505 (amsulostat) and peers

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

Trial design comparison

How SNT-5505 (amsulostat) reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
SNT-5505 (amsulostat)	Syntara	Small Molecule Other	Phase 2[ TODO: fill in ]	[ TODO: fill in ] (MESSAGE study — combination of SNT-5505 and ASTX727 in low-risk MDS; further design details not available in provided data)	[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	0
A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

Mechanism trade-offs· 2 classes comparedexpand ›

Mechanism	Speed to patient	Manufacturing	Best approved result	Durability	Moat
Fc Fusion ProteinFc-fusion trap	Off-the-shelf	Biologic	Eylea / Vabysmo class	Dosing-interval driven	High (incumbents)
Antisense oligonucleotideASO	Off-the-shelf	Synthetic	Approved (SMA/DMD)	Chronic dosing	Moderate

SNT-5505 (amsulostat)n = 0

Syntara·Small Molecule Other·Phase 2·[ TODO: fill in ]

Design: [ TODO: fill in ] (MESSAGE study — combination of SNT-5505 and ASTX727 in low-risk MDS; further design details not available in provided data)
Primary endpoint: [ TODO: fill in ]
Dosing: [ TODO: fill in ]
Eligibility: [ TODO: fill in ]

A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in Indian = —

Bristol-Myers Squibb·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemian = —

National Cancer Institute (NCI)·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïven = —

Celgene·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemian = —

Otsuka Australia Pharmaceutical Pty Ltd·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participantsn = —

Bristol-Myers Squibb·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusionsn = —

Bristol-Myers Squibb·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusionsn = —

Takeda·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusionsn = —

Takeda·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)n = —

Geron Corporation·—·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)n = —

Bristol-Myers Squibb·—·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromesn = —

Associazione Qol-one·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AMLn = —

Montefiore Medical Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDSn = —

First Affiliated Hospital of Zhejiang University·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromesn = —

Hansoh BioMedical R&D Company·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Combining Active and Passive DNA Hypomethylationn = —

Kirsten Grønbæk·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemian = —

Halia Therapeutics, Inc.·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasmsn = —

GCP-Service International West GmbH·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndromen = —

M.D. Anderson Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusionsn = —

University of Leipzig·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)n = —

National Cancer Institute (NCI)·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemian = —

M.D. Anderson Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasmsn = —

University of Southern California·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Oral-ATO for TP53-mutated Myeloid Malignanciesn = —

The University of Hong Kong·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantationn = —

Hannah Choe, MD·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndromen = —

GlaxoSmithKline·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromesn = —

Pharmacosmos A/S·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blastsn = —

M.D. Anderson Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)n = —

National Cancer Institute (NCI)·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutationsn = —

Abhay Singh, MD MPH·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)n = —

M.D. Anderson Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of TAK-226 for Transfusion-Dependent Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromesn = —

Takeda·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)n = —

Takeda·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)n = —

National Cancer Institute (NCI)·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)n = —

Lixte Biotechnology Holdings, Inc.·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDSn = —

Peking Union Medical College Hospital·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)n = —

Rigel Pharmaceuticals·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Pacritinib With Aza for Upfront Myelodysplastic Syndromen = —

Thomas Jefferson University·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

BS
A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India
Phase 4
Bristol-Myers Squibb·Active, not recruiting·Primary completion 16 Dec 2028·NCT05891249
NC
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Phase 3
National Cancer Institute (NCI)·Active, not recruiting·Primary completion 8 July 2019·NCT00843882
C
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
Phase 3
Celgene·Active, not recruiting·Primary completion 31 Mar 2023·NCT03682536
OA
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Phase 3
Otsuka Australia Pharmaceutical Pty Ltd·Active, not recruiting·Primary completion 6 Dec 2024·NCT05883956
BS
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
Phase 3
Bristol-Myers Squibb·Active, not recruiting·Primary completion 1 Oct 2025·NCT06045689
BS
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Phase 3
Bristol-Myers Squibb·Active, not recruiting·Primary completion 24 Mar 2028·NCT05949684
T
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Phase 3
Takeda·Recruiting·Primary completion 1 May 2028·NCT06499285
T
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Phase 3
Takeda·Recruiting·Primary completion 30 Apr 2029·NCT07422480
GC
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
PHASE2/PHASE3
Geron Corporation·Active, not recruiting·Primary completion 13 Oct 2023·NCT02598661
BS
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
PHASE2/PHASE3
Bristol-Myers Squibb·Active, not recruiting·Primary completion 31 July 2028·NCT05469737
AQ
Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes
Phase 2
Associazione Qol-one·Active, not recruiting·Primary completion 2 Feb 2017·NCT02912208
MC
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Phase 2
Montefiore Medical Center·Recruiting·Primary completion 20 Dec 2023·NCT05184842
FA
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
Phase 2
First Affiliated Hospital of Zhejiang University·Recruiting·Primary completion 19 Oct 2025·NCT06046313
HB
A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Phase 2
Hansoh BioMedical R&D Company·Not yet recruiting·Primary completion 30 Oct 2025·NCT06594965
KG
Combining Active and Passive DNA Hypomethylation
Phase 2
Kirsten Grønbæk·Recruiting·Primary completion 1 Dec 2025·NCT03999723
H,
A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia
Phase 2
Halia Therapeutics, Inc.·Active, not recruiting·Primary completion 8 Jan 2026·NCT07052006
GI
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
Phase 2
GCP-Service International West GmbH·Active, not recruiting·Primary completion 1 May 2026·NCT06243458
MA
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Phase 2
M.D. Anderson Cancer Center·Recruiting·Primary completion 30 June 2026·NCT01624805
UO
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
Phase 2
University of Leipzig·Recruiting·Primary completion 31 July 2026·NCT05384691
NC
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
Phase 2
National Cancer Institute (NCI)·Not yet recruiting·Primary completion 31 Aug 2026·NCT05554419
MA
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Phase 2
M.D. Anderson Cancer Center·Recruiting·Primary completion 31 Dec 2026·NCT04239157
UO
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
Phase 2
University of Southern California·Recruiting·Primary completion 31 Dec 2026·NCT06063486
TU
Oral-ATO for TP53-mutated Myeloid Malignancies
Phase 2
The University of Hong Kong·Recruiting·Primary completion 1 Feb 2027·NCT06778187
HC
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Phase 2
Hannah Choe, MD·Recruiting·Primary completion 1 June 2027·NCT07249346
G
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Phase 2
GlaxoSmithKline·Recruiting·Primary completion 14 July 2027·NCT06847867
PA
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
Phase 2
Pharmacosmos A/S·Recruiting·Primary completion 1 Oct 2027·NCT05693909
MA
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
Phase 2
M.D. Anderson Cancer Center·Recruiting·Primary completion 31 Dec 2027·NCT05365035
NC
A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)
Phase 2
National Cancer Institute (NCI)·Not yet recruiting·Primary completion 31 Dec 2027·NCT07463820
AS
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Phase 2
Abhay Singh, MD MPH·Recruiting·Primary completion 1 Jan 2028·NCT06630221
MA
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Phase 2
M.D. Anderson Cancer Center·Recruiting·Primary completion 1 Feb 2028·NCT01515527
T
A Study of TAK-226 for Transfusion-Dependent Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes
Phase 2
Takeda·Not yet recruiting·Primary completion 26 June 2028·NCT07319845
T
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Phase 2
Takeda·Recruiting·Primary completion 30 Oct 2029·NCT04419649
NC
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
Phase 2
National Cancer Institute (NCI)·Not yet recruiting·Primary completion 26 Apr 2030·NCT07153497
LB
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
PHASE1/PHASE2
Lixte Biotechnology Holdings, Inc.·Recruiting·Primary completion 1 May 2021·NCT03886662
PU
A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS
PHASE1/PHASE2
Peking Union Medical College Hospital·Not yet recruiting·Primary completion 1 Oct 2025·NCT06020833
R
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
PHASE1/PHASE2
Rigel Pharmaceuticals·Recruiting·Primary completion 1 Aug 2026·NCT05308264
TJ
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
PHASE1/PHASE2
Thomas Jefferson University·Not yet recruiting·Primary completion 1 Jan 2027·NCT07387354